Key Points
- Director Elizabeth Hoff sold 4,200 shares on Nov. 18 at an average price of $45.10 for total proceeds of $189,420, cutting her holding by 13.38% to 27,189 shares (≈$1.23M).
- Artivion beat estimates with quarterly EPS $0.16 vs. $0.14 expected and revenue of $113.39M (up 18.9% YoY), but still reported a negative net margin of 4.43%.
- The stock trades near $44.69 (52-week range $21.97–$48.04) with a market cap of ~$2.12B, and analysts have a consensus "Moderate Buy" rating with a $49.11 target.
Artivion, Inc. (NYSE:AORT - Get Free Report) Director Elizabeth Hoff sold 4,200 shares of the firm's stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $45.10, for a total transaction of $189,420.00. Following the sale, the director owned 27,189 shares in the company, valued at approximately $1,226,223.90. This represents a 13.38% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Artivion Price Performance
Shares of AORT stock traded up $0.06 during mid-day trading on Thursday, hitting $44.69. 8,607 shares of the stock were exchanged, compared to its average volume of 431,710. Artivion, Inc. has a 52-week low of $21.97 and a 52-week high of $48.04. The company has a quick ratio of 3.48, a current ratio of 4.78 and a debt-to-equity ratio of 0.52. The company has a market cap of $2.12 billion, a PE ratio of -106.42 and a beta of 1.65. The firm has a fifty day moving average of $42.85 and a 200 day moving average of $36.72.
Artivion (NYSE:AORT - Get Free Report) last posted its quarterly earnings results on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.02. The firm had revenue of $113.39 million for the quarter, compared to analyst estimates of $110.71 million. Artivion had a negative net margin of 4.43% and a positive return on equity of 5.70%. Artivion's revenue was up 18.9% compared to the same quarter last year. Artivion has set its FY 2025 guidance at EPS. Research analysts anticipate that Artivion, Inc. will post 0.37 earnings per share for the current year.
Analyst Upgrades and Downgrades
Several equities research analysts recently commented on AORT shares. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Artivion in a report on Wednesday, October 8th. Oppenheimer reaffirmed an "outperform" rating and issued a $50.00 target price on shares of Artivion in a research note on Friday, November 7th. Wall Street Zen raised shares of Artivion from a "buy" rating to a "strong-buy" rating in a research report on Saturday, November 15th. Stifel Nicolaus increased their target price on shares of Artivion from $40.00 to $46.00 and gave the stock a "buy" rating in a research note on Monday, September 29th. Finally, JMP Securities upped their price objective on shares of Artivion from $42.00 to $47.00 and gave the stock a "market outperform" rating in a report on Friday, October 10th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Artivion presently has a consensus rating of "Moderate Buy" and a consensus price target of $49.11.
Read Our Latest Stock Analysis on AORT
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Caitong International Asset Management Co. Ltd acquired a new stake in Artivion during the 3rd quarter worth approximately $27,000. Aster Capital Management DIFC Ltd raised its stake in shares of Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company's stock valued at $27,000 after acquiring an additional 519 shares in the last quarter. MCF Advisors LLC raised its stake in shares of Artivion by 109.3% in the first quarter. MCF Advisors LLC now owns 1,176 shares of the company's stock valued at $29,000 after acquiring an additional 614 shares in the last quarter. Smartleaf Asset Management LLC boosted its holdings in Artivion by 47.7% in the second quarter. Smartleaf Asset Management LLC now owns 1,667 shares of the company's stock valued at $52,000 after purchasing an additional 538 shares during the period. Finally, State of Wyoming purchased a new stake in Artivion during the 3rd quarter worth about $80,000. Institutional investors and hedge funds own 86.37% of the company's stock.
Artivion Company Profile
(
Get Free Report)
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
